An MTP Inhibitor That Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits

See allHide authors and affiliations

Science  23 Oct 1998:
Vol. 282, Issue 5389, pp. 751-754
DOI: 10.1126/science.282.5389.751

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Patients with abetalipoproteinemia, a disease caused by defects in the microsomal triglyceride transfer protein (MTP), do not produce apolipoprotein B–containing lipoproteins. It was hypothesized that small molecule inhibitors of MTP would prevent the assembly and secretion of these atherogenic lipoproteins. To test this hypothesis, two compounds identified in a high-throughput screen for MTP inhibitors were used to direct the synthesis of a highly potent MTP inhibitor. This molecule (compound 9) inhibited the production of lipoprotein particles in rodent models and normalized plasma lipoprotein levels in Watanabe-heritable hyperlipidemic (WHHL) rabbits, which are a model for human homozygous familial hypercholesterolemia. These results suggest that compound 9, or derivatives thereof, has potential applications for the therapeutic lowering of atherogenic lipoprotein levels in humans.

  • * To whom correspondence should be addressed. E-mail: Wetterau_John_R{at} (J.R.W.) and biller{at} (S.A.B.)

  • Present address: GelTex Pharmacueticals, 9 Fourth Avenue, Waltham, MA 02154, USA.

  • Present address: 14 Royal College of Surgeons, Dublin, Ireland.

  • § Present address: Department of Chemistry, 516 Physical Sciences 1, University of California, Irvine, CA 92697, USA.

View Full Text